Cancer patients face competing risks of cancer death and CVD. Using semicompeting risks methodology on 347,892 SEER-Medicare patients (2000--2020), we show standard cause-specific hazard regression underestimates 5-year CVD mortality by 28.
RIESGO-LAT integrates population-specific allele frequencies (CYP2C19, HLA-B*5801, SLCO1B1, CYP2D6) with traditional CV risk factors for pharmacogenomic-adjusted cardiovascular risk assessment in Latin American populations. Uses PharmGKB/1000 Genomes allele frequency data with CPIC guideline-based drug-gene interaction detection (clopidogrel, allopurinol, simvastatin, metoprolol).
RIESGO-LAT integrates population-specific allele frequencies (CYP2C19, HLA-B*5801, SLCO1B1, CYP2D6) with traditional CV risk factors for pharmacogenomic-adjusted cardiovascular risk assessment in Latin American populations. Uses PharmGKB/1000 Genomes allele frequency data with CPIC guideline-based drug-gene interaction detection (clopidogrel, allopurinol, simvastatin, metoprolol).
Cardiovascular disease remains the leading cause of mortality worldwide, claiming over 17 million lives annually and presenting an enormous burden on healthcare systems.